Novel role for tumor-induced expansion of myeloid-derived cells in cancer cachexia

Journal of Immunology

Volumn 192, Issue 12, 2014, Pages 6111-6119

  Cuenca, Alex G ^a   Cuenca, Angela L ^a   Winfield, Robert D ^a   Joiner, Dallas N ^a   Gentile, Lori ^a   Delano, Matthew J ^a   Kelly Scumpia, Kindra M ^a   Scumpia, Philip O ^a   Matheny, Michael K ^a   Scarpace, Philip J ^a   Vila, Lizette ^a   Efron, Philip A ^a   La Face, Drake M ^b   Moldawer, Lyle L ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CD11B ANTIGEN; CD31 ANTIGEN; HAPTOGLOBIN; HEMOPEXIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; REACTIVE OXYGEN METABOLITE; SERUM AMYLOID A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; BREAST CARCINOMA; CACHEXIA; CANCER MORTALITY; CANCER SURVIVAL; CELL EXPANSION; COLON ADENOCARCINOMA; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOTOXEMIA; ENERGY EXPENDITURE; ENERGY METABOLISM; FEMALE; IN VIVO STUDY; INNATE IMMUNITY; LEWIS CARCINOMA; LIPID METABOLISM; LYMPHOCYTE PROLIFERATION; MOUSE; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; OXYGEN CONSUMPTION; PATHOGENESIS; POLYMICROBIAL SEPSIS; PRIORITY JOURNAL; PROTEIN METABOLISM; SEPSIS; SPLEEN CELL; SUPPRESSOR CELL; TUMOR VOLUME;

ANIMALS; CACHEXIA; CELL LINE, TUMOR; FEMALE; IMMUNE TOLERANCE; MICE; MICE, INBRED BALB C; MYELOID CELLS; NEOPLASMS, EXPERIMENTAL;

EID: 84902191065     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1302895     Document Type: Article

References (42)

1. Fearon, K., F. Strasser, S. D. Anker, I. Bosaeus, E. Bruera, R. L. Fainsinger, A. Jatoi, C. Loprinzi, N. MacDonald, G. Mantovani, et al. 2011. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 12:489-495.
2. Winfield, R. D., M. J. Delano, K. Pande, P. O. Scumpia, D. Laface, and L. L. Moldawer. 2008. Myeloid-derived suppressor cells in cancer cachexia syndrome: a new explanation for an old problem. JPEN J. Parenter. Enteral Nutr. 32:651-655.
3. Seruga, B., H. Zhang, L. J. Bernstein, and I. F. Tannock. 2008. Cytokines and their relationship to the symptoms and outcome of cancer. Nat. Rev. Cancer 8:887-899.
4. Moldawer, L. L., and E. M. Copeland, III. 1997. Proinflammatory cytokines, nutritional support, and the cachexia syndrome: interactions and therapeutic options. Cancer 79:1828-1839.
5. Ambrus, J. L., C. M. Ambrus, I. B. Mink, and J. W. Pickren. 1975. Causes of death in cancer patients. J. Med. 6:61-64.
6. Penna, F., V. G. Minero, D. Costamagna, G. Bonelli, F. M. Baccino, and P. Costelli. 2010. Anti-cytokine strategies for the treatment of cancer-related anorexia and cachexia. Expert Opin. Biol. Ther. 10:1241-1250.
7. Robinson, D. W., Jr., D. F. Eisenberg, D. Cella, N. Zhao, C. De Boer, and M. De Witte. 2008. The prognostic significance of patient-reported outcomes in pancreatic cancer cachexia. J. Support. Oncol. 6:283-290.
8. Wiedenmann, B., P. Malfertheiner, H. Friess, P. Ritch, J. Arseneau, G. Mantovani, F. Caprioni, E. Van Cutsem, D. Richel, M. De Witte, et al. 2008. A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia. J. Support. Oncol. 6:18-25.
9. Van Zaanen, H. C., H. M. Lokhorst, L. A. Aarden, H. J. Rensink, S. O. Warnaar, J. Van Der Lelie, and M. H. Van Oers. 1998. Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose-escalating study. Br. J. Haematol. 102:783-790.
10. Allavena, P., G. Germano, F. Marchesi, and A. Mantovani. 2011. Chemokines in cancer related inflammation. Exp. Cell Res. 317:664-673.
11. Mantovani, A. 2010. Molecular pathways linking inflammation and cancer. Curr. Mol. Med. 10:369-373.
12. Solinas, G., G. Germano, A. Mantovani, and P. Allavena. 2009. Tumorassociated macrophages (TAM) as major players of the cancer-related inflammation. J. Leukoc. Biol. 86:1065-1073.
13. Gabrilovich, D. I., and S. Nagaraj. 2009. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9:162-174.
14. Nagaraj, S., M. Collazo, C. A. Corzo, J. I. Youn, M. Ortiz, D. Quiceno, and D. I. Gabrilovich. 2009. Regulatory myeloid suppressor cells in health and disease. Cancer Res. 69:7503-7506.
15. Cripps, J. G., and J. D. Gorham. 2011. MDSC in autoimmunity. Int. Immunopharmacol. 11:789-793.
16. Oberholzer, A., C. Oberholzer, K. S. Bahjat, R. Ungaro, C. L. Tannahill, M. Murday, F. R. Bahjat, Z. Abouhamze, V. Tsai, D. La Face, et al. 2002. Increased survival in sepsis by in vivo adenovirus-induced expression of IL-10 in dendritic cells. J. Immunol. 168:3412-3418.
17. Scumpia, P. O., P. F. McAuliffe, K. A. O'Malley, R. Ungaro, T. Uchida, T. Matsumoto, D. G. Remick, M. J. Clare-Salzler, L. L. Moldawer, and P. A. Efron. 2005. CD11c+ dendritic cells are required for survival in murine polymicrobial sepsis. J. Immunol. 175:3282-3286.
18. Youn, J. I., S. Nagaraj, M. Collazo, and D. I. Gabrilovich. 2008. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J. Immunol. 181:5791-5802.
19. Nagaraj, S., K. Gupta, V. Pisarev, L. Kinarsky, S. Sherman, L. Kang, D. L. Herber, J. Schneck, and D. I. Gabrilovich. 2007. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat. Med. 13:828-835.
20. Oldenburg, H. S., M. A. Rogy, D. D. Lazarus, K. J. Van Zee, B. P. Keeler, R. A. Chizzonite, S. F. Lowry, and L. L. Moldawer. 1993. Cachexia and the acute-phase protein response in inflammation are regulated by interleukin-6. Eur. J. Immunol. 23:1889-1894.
21. Delano, M. J., and L. L. Moldawer. 2006. The origins of cachexia in acute and chronic inflammatory diseases. Nutr. Clin. Pract. 21:68-81.
22. Pande, K., R. Ueda, T. Machemer, M. Sathe, V. Tsai, E. Brin, M. J. Delano, N. Van Rooijen, T. K. McClanahan, J. E. Talmadge, et al. 2009. Cancer-induced expansion and activation of CD11b+ Gr-1+ cells predispose mice to adenoviraltriggered anaphylactoid-type reactions. Mol. Ther. 17:508-515.
23. Delano, M. J., P. O. Scumpia, J. S. Weinstein, D. Coco, S. Nagaraj, K. M. Kelly-Scumpia, K. A. O'Malley, J. L. Wynn, S. Antonenko, S. Z. Al-Quran, et al. 2007. MyD88-dependent expansion of an immature GR-1 (+) CD11b (+) population induces T cell suppression and Th2 polarization in sepsis. J. Exp. Med. 204:1463-1474.
24. Danai, P. A., M. Moss, D. M. Mannino, and G. S. Martin. 2006. The epidemiology of sepsis in patients with malignancy. Chest 129:1432-1440.
25. Safdar, A., and D. Armstrong. 2001. Infectious morbidity in critically ill patients with cancer. Crit. Care Clin. 17:531-570, vii-viii.
26. Mauti, L. A., M. A. Le Bitoux, K. Baumer, J. C. Stehle, D. Golshayan, P. Provero, and I. Stamenkovic. 2011. Myeloid-derived suppressor cells are implicated in regulating permissiveness for tumor metastasis during mouse gestation. J. Clin. Invest. 121:2794-2807.
27. Cuenca, A. G., M. J. Delano, K. M. Kelly-Scumpia, C. Moreno, P. O. Scumpia, D. M. Laface, P. G. Heyworth, P. A. Efron, and L. L. Moldawer. 2011. A paradoxical role for myeloid-derived suppressor cells in sepsis and trauma. Mol. Med. 17:281-292.
28. Umemura, N., M. Saio, T. Suwa, Y. Kitoh, J. Bai, K. Nonaka, G. F. Ouyang, M. Okada, M. Balazs, R. Adany, et al. 2008. Tumor-infiltrating myeloid-derived suppressor cells are pleiotropic-inflamed monocytes/macrophages that bear M1- and M2-type characteristics. J. Leukoc. Biol. 83:1136-1144.
29. Ko, J. S., P. Rayman, J. Ireland, S. Swaidani, G. Li, K. D. Bunting, B. Rini, J. H. Finke, and P. A. Cohen. 2010. Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. Cancer Res. 70:3526-3536.
30. Sinha, P., V. K. Clements, S. K. Bunt, S. M. Albelda, and S. Ostrand-Rosenberg. 2007. Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J. Immunol. 179:977-983.
31. Sherry, B. A., J. Gelin, Y. Fong, M. Marano, H. Wei, A. Cerami, S. F. Lowry, K. G. Lundholm, and L. L. Moldawer. 1989. Anticachectin/tumor necrosis factor-alpha antibodies attenuate development of cachexia in tumor models. FASEB J. 3:1956-1962.
32. Bennani-Baiti, N., and D. Walsh. 2011. Animal models of the cancer anorexiacachexia syndrome. Support. Care Cancer 19:1451-1463.
33. Marigo, I., L. Dolcetti, P. Serafini, P. Zanovello, and V. Bronte. 2008. Tumorinduced tolerance and immune suppression by myeloid derived suppressor cells. Immunol. Rev. 222:162-179.
34. Zhao, X., L. Rong, X. Zhao, X. Li, X. Liu, J. Deng, H. Wu, X. Xu, U. Erben, P. Wu, et al. 2012. TNF signaling drives myeloid-derived suppressor cell accumulation. J. Clin. Invest. 122:4094-4104.
35. Dolcetti, L., E. Peranzoni, and V. Bronte. 2010. Measurement of myeloid cell immune suppressive activity. Curr. Protoc. Immunol. Chapter 14: Unit 14.17.
36. Capietto, A. H., S. Kim, D. E. Sanford, D. C. Linehan, M. Hikida, T. Kumosaki, D. V. Novack, and R. Faccio. 2013. Down-regulation of PLCg2-b-catenin pathway promotes activation and expansion of myeloid-derived suppressor cells in cancer. J. Exp. Med. 210:2257-2271.
37. Iclozan, C., S. Antonia, A. Chiappori, D. T. Chen, and D. Gabrilovich. 2013. Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer. Cancer Immunol. Immunother. 62:909-918.
38. Sanford, D. E., M. R. Porembka, R. Z. Panni, J. B. Mitchem, B. A. Belt, S. M. Plambeck-Suess, G. Lin, D. G. Denardo, R. C. Fields, W. G. Hawkins, et al. 2013. A study of zoledronic acid as neo-adjuvant, perioperative therapy in patients with resectable pancreatic ductal adenocarcinoma. J. Cancer Ther. 4:797-803.
39. Kusmartsev, S., and D. I. Gabrilovich. 2002. Immature myeloid cells and cancerassociated immune suppression. Cancer Immunol. Immunother. 51:293-298.
40. Kusmartsev, S., Z. Su, A. Heiser, J. Dannull, E. Eruslanov, H. Kübler, D. Yancey, P. Dahm, and J. Vieweg. 2008. Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma. Clin. Cancer Res. 14:8270-8278.
41. high suppressive monocytes in experimental autoimmune encephalomyelitis. J. Immunol. 179:5228-5237.
42. Scumpia, P. O., K. M. Kelly-Scumpia, M. J. Delano, J. S. Weinstein, A. G. Cuenca, S. Al-Quran, I. Bovio, S. Akira, Y. Kumagai, and L. L. Moldawer. 2010. Cutting edge: bacterial infection induces hematopoietic stem and progenitor cell expansion in the absence of TLR signaling. J. Immunol. 184:2247-2251